Hospital
Inspira Medical Centers, INC.
Inspira Medical Centers, INC. was paid $30.55M by Medicaid between Jan 2018 and Nov 2024, across 183 billing codes. Its largest line is 99284, emergency room visit (serious) — 31% of everything it billed.
33Billing provider infoINSPIRA MEDICAL CENTERS, INC.
ELMER, NJ 08318
ELMER, NJ 08318
33aNPI1255396024assigned 04/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$30.55M
24GClaims400,872
24DCodes billed183
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#48 of 93
Median peer was paid$30.60M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,781 | $3.99M | |
| 2019 | 50,360 | $3.92M | |
| 2020 | 39,684 | $3.18M | |
| 2021 | 57,220 | $4.38M | |
| 2022 | 68,749 | $5.29M | |
| 2023 | 76,473 | $5.60M | |
| 2024incomplete | 54,605 | $4.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 16,010 | 14,886 | $9.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 17,085 | 16,138 | $6.37M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 6,458 | 6,049 | $4.73M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 14% | 12,102 | 938 | $4.13M |
| G0378 | Hospital observation service, per hour | 5.9% | 2,433 | 1,926 | $1.81M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 3,268 | 3,151 | $746K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.8% | 2,961 | 1,722 | $536K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 599 | 583 | $418K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,398 | 3,266 | $189K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,787 | 8,088 | $159K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,081 | 7,439 | $137K |
| OP710 | <1% | 1,005 | 949 | $99K |
171 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,569 | $77K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,379 | $70K |
| OP279 | <1% | 3,327 | $65K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,297 | $65K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,508 | $64K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,536 | $61K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,957 | $54K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,537 | $54K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,787 | $52K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 630 | $43K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,717 | $41K |
| 76801 | <1% | 728 | $40K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 324 | $39K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,829 | $38K |
| 97602 | <1% | 449 | $36K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,554 | $35K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,353 | $34K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,210 | $28K |
| 76830 | Ultrasound, transvaginal | <1% | 379 | $28K |
| 11045 | <1% | 181 | $27K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 961 | $27K |
| 94760 | <1% | 18,969 | $25K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,738 | $25K |
| 80053 | Comprehensive metabolic panel | <1% | 8,488 | $25K |
| 73630 | <1% | 1,906 | $24K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 20,912 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,689 | $24K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,207 | $22K |
| 36000 | <1% | 4,406 | $22K | |
| 87631 | <1% | 1,187 | $21K | |
| OP259 | <1% | 18,590 | $20K | |
| 93041 | <1% | 3,579 | $19K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 947 | $18K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 602 | $17K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,983 | $17K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,745 | $17K |
| 95806 | <1% | 12 | $17K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,985 | $16K |
| 73564 | <1% | 1,013 | $16K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 297 | $15K |
| 82962 | <1% | 5,321 | $14K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 851 | $14K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 368 | $14K |
| 73610 | <1% | 1,379 | $14K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 361 | $13K |
| 93971 | <1% | 274 | $13K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 80 | $12K |
| 73130 | <1% | 1,096 | $12K | |
| 84484 | <1% | 3,698 | $11K | |
| J3490 | Unclassified drugs | <1% | 6,494 | $11K |
| 93975 | <1% | 321 | $10K | |
| 86901 | <1% | 890 | $9K | |
| 83880 | <1% | 1,544 | $9K | |
| 80076 | <1% | 5,610 | $9K | |
| 71250 | <1% | 112 | $8K | |
| 83690 | <1% | 6,991 | $7K | |
| 73030 | <1% | 602 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 688 | $6K |
| 97010 | <1% | 1,399 | $6K | |
| 81003 | <1% | 12,505 | $6K | |
| OP272 | <1% | 148 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,138 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 156 | $6K |
| 97161 | <1% | 122 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,380 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 347 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 786 | $5K |
| 83735 | <1% | 4,624 | $5K | |
| 73110 | <1% | 405 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 898 | $5K |
| 81025 | <1% | 7,295 | $5K | |
| 85610 | <1% | 2,488 | $5K | |
| 85730 | <1% | 1,799 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,118 | $4K |
| 86900 | <1% | 889 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,863 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,238 | $4K |
| 81001 | <1% | 7,265 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,238 | $3K |
| 86850 | <1% | 394 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 795 | $3K |
| 72110 | <1% | 111 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 338 | $2K |
| 87070 | <1% | 487 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,275 | $2K |
| 87186 | <1% | 819 | $2K | |
| 84702 | <1% | 643 | $2K | |
| A6457 | Tubular dressing with or without elastic, any width, per linear yard | <1% | 803 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 834 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 344 | $2K |
| 83605 | <1% | 815 | $2K | |
| 90714 | <1% | 360 | $2K | |
| OP250 | <1% | 3,713 | $2K | |
| 87081 | <1% | 1,225 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 607 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,224 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 810 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,316 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 26 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 188 | $2K |
| 96376 | <1% | 251 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,010 | $1K |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 1,052 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 145 | $1K |
| 85027 | <1% | 166 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 948 | $1K |
| 93970 | <1% | 12 | $950.97 | |
| 73590 | <1% | 84 | $927.04 | |
| 87077 | <1% | 531 | $887.90 | |
| 87210 | <1% | 1,494 | $883.92 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 941 | $836.95 |
| 87147 | <1% | 1,273 | $829.81 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 83 | $744.17 |
| 84703 | <1% | 884 | $689.04 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 573 | $672.85 |
| 94761 | <1% | 83 | $628.53 | |
| 73502 | <1% | 39 | $621.55 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 658 | $615.83 |
| 85379 | <1% | 511 | $583.99 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,514 | $533.12 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,283 | $489.71 |
| 82803 | <1% | 96 | $452.61 | |
| 87040 | <1% | 122 | $417.85 | |
| 87486 | <1% | 60 | $399.05 | |
| 87581 | <1% | 60 | $399.05 | |
| 80320 | <1% | 232 | $394.60 | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | <1% | 278 | $392.16 |
| 82248 | <1% | 58 | $352.24 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 16 | $333.42 |
| L2999 | Lower extremity orthoses, not otherwise specified | <1% | 193 | $325.84 |
| 87071 | <1% | 65 | $311.97 | |
| 29125 | <1% | 13 | $223.26 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 905 | $219.24 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 61 | $193.14 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 446 | $180.70 |
| 82375 | <1% | 96 | $172.14 | |
| 85055 | <1% | 36 | $155.74 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 729 | $152.27 |
| 82550 | <1% | 142 | $148.85 | |
| 97116 | <1% | 18 | $136.46 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,458 | $135.15 |
| OP637 | <1% | 1,227 | $134.03 | |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 222 | $132.80 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 132 | $128.71 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 65 | $105.22 |
| 83050 | <1% | 96 | $88.02 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 46 | $81.31 |
| 87205 | <1% | 50 | $77.90 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 68 | $77.02 |
| 82330 | <1% | 13 | $75.50 | |
| A6252 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 606 | $74.99 |
| OP270 | <1% | 15 | $74.29 | |
| 87073 | <1% | 56 | $55.96 | |
| 73080 | <1% | 13 | $48.81 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 37 | $38.83 |
| 85018 | <1% | 113 | $23.04 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $21.63 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 50 | $17.00 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 26 | $15.67 |
| 85008 | <1% | 244 | $12.34 | |
| A9270 | Non-covered item or service | <1% | 391 | $9.39 |
| 82270 | <1% | 14 | $8.26 | |
| 84100 | <1% | 13 | $6.33 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 24 | $5.23 |
| 86140 | <1% | 14 | $3.99 | |
| 82947 | <1% | 24 | $3.39 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16 | $2.85 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 37 | $2.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 14 | $1.00 |
| 90832 | Psychotherapy session, about 30 minutes | 0% | 34 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialO'CONNELL, JAMES (DIRECTOR REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Inspira Medical Centers, INC. | Vineland, NJ | $227.07M |
| Inspira Medical Centers, INC. | Mullica Hill, NJ | $56.65M |
| Inspira Medical Centers, INC. | Woodbury, NJ | $27.14M |
| Inspira Health Network Medical Group, P.C. | Glassboro, NJ | $5.22M |
| Inspira Medical Centers, INC. | Bridgeton, NJ | $73K |
| Inspira Medical Centers, INC. | Woodbury, NJ | $33K |
| Inspira Medical Centers, INC. | Woodbury, NJ | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.